Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ciresp.2017.12.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of Surgical Cases of Lung Cancer Admitted in Shiraz Referral Hospitals, Southern Iran in 2009-2022.
Cancer Rep (Hoboken)
March 2025
Thoracic and Vascular Surgery Research Center, Shiraz University of Medical Science, Shiraz, Iran.
Introduction: Globally, lung cancer is one of the most commonly diagnosed cancers and continues to take the lead in cancer-related mortality rates. This study aims to provide the latest statistics on the clinical, histopathological, and epidemiological features of lung cancer patients who underwent surgical resection in referral hospitals in Southern Iran.
Method: In this retrospective study, records of all patients with operable primary and secondary lung cancer who underwent surgical resection of the lung in Shiraz hospitals, located in Southern Iran from November 2009 to May 2022 were screened.
EWS-RNA Binding Protein 1: Structural Insights into Ewing Sarcoma by Conformational Dynamics Investigations.
Curr Cancer Drug Targets
March 2025
The Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH 43205, USA.
Background: Prior research has demonstrated that proteins play a significant role in the prognosis and treatments of various sarcomas, including Ewing sarcoma through the interplay of downstream signaling cascades. However, there is limited understanding about the strcucture conformation of EWSR1 and its structural implication in the prognosis of Ews-ing Sarcoma by interaction with RNA molecules.
Aims: The primary goal of ongoing research is to determine how EWSR1 contributes to Ewing sarcoma.
The Combination of PARP and Topoisomerase 1 Inhibitors Improves Radiation Therapy for Ewing Sarcoma.
Cancer Sci
March 2025
Department of Chemical Biology and Therapeutics, SJCRH, Memphis, Tennessee, USA.
Although primary tumor control rates after surgery and/or radiation therapy (RT) are generally high in patients with Ewing sarcoma (EWS), those with unresectable tumors have failure rates approaching 30% and experience poorer outcomes. Additionally, although metastatic site irradiation is associated with improved survival, dose, and volume effects influence the long-term toxicity risk. Consequently, it is important to identify novel systemic agents to enhance the therapeutic ratio of RT.
View Article and Find Full Text PDFClinical features, treatment and prognosis of primary pulmonary rhabdomyosarcoma: A systemic review.
BMC Pediatr
March 2025
Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Background: Primary pulmonary rhabdomyosarcoma (RMS), a rare soft tissue sarcoma, is characterized by a high recurrence rate and a poor prognosis. This systematic review aims to summarize the clinical characteristics, pathological features, treatment, and clinical outcomes of primary pulmonary RMS, and to analyze prognostic-related risk factors to provide robust evidence for future treatment strategies.
Methods: Five databases (MEDLINE, Scopus, the Cochrane Central Register of Controlled Trials, EMBASE, and Web of Science) were searched using the relevant terms including "pulmonary", "lung", "alveolar", "ERMS", "ARMS", "RMS" and "rhabdomyosarcoma".
Background: Soft tissue sarcomas (STS) are rare, heterogeneous neoplasms often not optimally managed by teams without sarcoma expertise. Between 40 % and 50 % of primary resections for extremity sarcomas occur without prior biopsy, resulting in inadequate excisions, termed "unplanned resections" or "whoops surgery."
Objective: To determine the rate of unplanned resections in extremity STS referred to a high-volume sarcoma center and evaluate their impact on oncological outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!